Edoxaban, a reversible and direct inhibitor of factor Xa, is used to reduce the risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF)
Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patien...
Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant ...
Marco Proietti,1,2 Gregory YH Lip1,3 1University of Birmingham Institute of Cardiovascular Sciences,...
INTRODUCTION: Oral anticoagulation is central to the management of patients with atrial fibrillation...
Edoxaban was noninferior to warfarin for preventing stroke or systemic embolism in atrial fibrillati...
The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Edoxaban...
BackgroundEdoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long...
Summary Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical developmen...
1.1 Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke ...
Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and syste...
Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patien...
Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant ...
Marco Proietti,1,2 Gregory YH Lip1,3 1University of Birmingham Institute of Cardiovascular Sciences,...
INTRODUCTION: Oral anticoagulation is central to the management of patients with atrial fibrillation...
Edoxaban was noninferior to warfarin for preventing stroke or systemic embolism in atrial fibrillati...
The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Edoxaban...
BackgroundEdoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long...
Summary Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical developmen...
1.1 Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke ...
Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and syste...
Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patien...
Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...